Tegra118 Selected by Challenger to Strengthen Revenue and Invoice Management
Tegra118, a top provider of wealth and asset management technology solutions – and a portfolio company of Motive Partners, a specialist private equity firm – announced today that Challenger is now a Tegra118 client for its comprehensive, cloud-based billing, revenue management and reporting solution. The largest annuity provider, and one of the fastest growing fund managers in Australia, Challenger will rely on Tegra118’s Advantage Fee™ platform to improve quality and productivity of invoice processing, increase transparency and accuracy on complex fee schedules, and streamline interfaces between accounting systems – all while enhancing client service and support.
“Challenger is a premier investment management firm and a top retirement income specialist, and we’re thrilled to be selected as its trusted partner,” said Cheryl Nash, CEO, Tegra118. “Our solution streamlines and automates fee calculations, verification and client onboarding workflow. Through our partnership with Suite2go in Australia, we’re connecting with the Australian financial services market to deliver technology solutions that address critical business needs. Challenger is confidently investing in our technology to help replace manual processes through an integrated solution that supports its large volume of fee calculations, verification and client onboarding workflow. We’re excited to work with Challenger and the opportunity to grow Tegra118’s presence in Australia.”
Advantage Fee™ from Tegra118 helps protect the bottom line with a comprehensive customer billing and revenue management solution. It supports organizations worldwide to manage multiple invoicing structures accurately, quickly and cost efficiently, while also accommodating the new generations of fee and account structures. With transparent and sophisticated reporting, analysis and dashboards, information can be leveraged throughout the enterprise to bolster better decision making.
“Given the ever-evolving wealth and asset management landscape, and the need for strong oversight of fees, Challenger needed a trusted technology partner to help us optimize efficiencies, minimize manual processes and associated risks,” says David Mackaway, Group Chief Operating Officer, Challenger. “Tegra118 and its Advantage Fee™ solution are the ideal match for our business needs today and into the future.”
For more information about Tegra118’s revenue and invoice management solutions, visit: Tegra118 Tools: Benefits & Features
About Tegra118
Tegra118 is an industry leading provider of software solutions to the wealth and asset management industry with a vast network of broker-dealers, asset managers, and custodians and trading interfaces. Its technology platform provides portfolio management, trading, accounting, rebalancing and reporting for managed accounts. Tegra118 also provides modular, goals-based financial planning, performance reporting and fee billing software for financial advisors and asset managers using modern API-based open technology. Tegra118 is committed to delivering powerful solutions that set a new standard for how people interact with, manage, and grow their wealth.
Tegra118 is a Motive Partners company, a specialist private equity firm with offices in New York City and London, focused on technology-enabled business and financial services companies. For more information, please visit www.tegra118.com.
About Challenger
Challenger Limited (Challenger) is an investment management firm focusing on providing customers with financial security for retirement. Challenger operates two core investment businesses, a fiduciary Funds Management division and an APRA-regulated Life division. Challenger Life Company Limited (Challenger Life) is Australia's largest provider of annuities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005228/en/
Contact information
Media Relations:
Tricia Viola
Vice President, Marketing
Tegra118
Tel: 201 253 3389
tricia.viola@fiserv.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 14:00:00 EET | Press release
The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what and how people will be drinking in 2026. “Gen Z isn’t drinking less, they’re simply drinking earlier, lighter, and with more intent
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 14:00:00 EET | Press release
AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, Chair of AdvanCell. “Her leadership and experience positions AdvanCell to drive its next phase of growth, with the United States now a major strategic focus as the company advances 212Pb
MSCI Announces Baer Pettit to Retire as President17.11.2025 14:00:00 EET | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s strategy and success,” said MSCI Chairman and CEO Henry Fernandez. “I would like to thank Bae
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 13:58:00 EET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom